Compare Adecoagro SA (AGRO) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adecoagro SA vs Inovio Pharmaceuticals Inc — how do they compare? Adecoagro SA trades at $9.26 (market cap $1.36B), while Inovio Pharmaceuticals Inc trades at $0.76 (market cap $78.55M). The key difference: Adecoagro SA is far larger — about 17.3× Inovio Pharmaceuticals Inc's market cap, and Adecoagro SA pays a 3.15% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AGRO | INO | |
|---|---|---|
Market Cap | $1.36B | $78.55M |
Sector | Technology | Health |
52-Week High | $15.25 | $2.87 |
52-Week Low | $7.13 | $0.66 |
Enterprise Value | $3.39B | $49.56M |
Dividend Yield | 3.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AGRO is trading at $9.01, down 6.73% today, with a bearish technical outlook despite attractive valuation ratios (P/S: 0.71, P/B: 0.77). The company reported mixed quarterly results with one beat and three misses in recent quarters, while showing improved adjusted EBITDA of $172.5 million in Q2 2026. Recent expansion via the Caarapó mill acquisition and Profertil integration provides growth catalysts amid commodity volatility.
The stock presents a value opportunity with below-market multiples but faces execution risks from negative earnings momentum and high leverage. Analyst consensus is mixed with 37.5% buy ratings and a $12.12 price target, suggesting 35% upside potential if operational improvements materialize.
INO trades at $0.76, up 2.74% today, but remains in a bearish technical trend. The company shows minimal revenue of $65K against high operating losses, with a net income margin of -130,000%. Recent quarterly EPS has beaten expectations. Analyst consensus is bullish with a $3.25 price target, but the stock faces significant fundamental challenges including negative cash flow and high valuation multiples.
The outlook hinges on FDA approval of INO-3107 in October 2026, a binary event that could drive substantial upside. However, persistent cash burn, negative profitability, and ongoing shareholder litigation present high risks. Investors should weigh the potential catalyst against the company's weak financial health and operational execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adecoagro SA
Adecoagro is a South American agricultural company. It operates a diversified business including farming crops, rice, and dairy, as well as producing sugar, ethanol, and renewable energy from its industrial facilities.
Read more on AGRO →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
